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Juan F. Viles-Gonzalez, MD,y Jonathan L. Halperin, MDzSEE PAGE 1541I n patients with atrial ﬁbrillation (AF), loss oforganized atrial contraction and accelerated ven-tricular rate can have both immediate and long-
term adverse consequences, including deterioration
of hemodynamics, progressive atrial and ventricular
dysfunction, and an ongoing risk of ischemic stroke
and systemic embolic events (SEEs). The principal
goals of therapy are control of symptoms and preven-
tion of thromboembolism.
The AFFIRM (Atrial Fibrillation Follow-Up Inves-
tigation of Rhythm Management) trial and other
studies demonstrated that both rate control and
rhythm control strategies improve symptoms in pa-
tients with AF, but neither of these strategies is
associated with better survival or a lower risk of
ischemic stroke than the other (1). Patients with AF
and additional risk factors for thromboembolism
require long-term anticoagulation, even after sinus
rhythm has been restored. The 2014 American College
of Cardiology/American Heart Association/Heart
Rhythm Society AF guidelines recommend antiar-
rhythmic drug therapy to reduce the frequency and
duration of episodes and improve quality of life
in patients with paroxysmal or persistent AF (2).
The class III antiarrhythmic drug, amiodarone, is
currently the most effective available agent. Amio-
darone is recommended for patients with frequent,*Editorials published in the Journal of the American College of Cardiology
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with structural heart disease.
The clinical utility of amiodarone is limited by
its potential toxicity, including cutaneous, ocular,
thyroid, hepatic, neurological, and pulmonary side
effects, some of which are dose-related, and by a
possible association with an increased risk of neo-
plasia. Pharmacokinetic interactions with other drugs
further complicate therapy. Amiodarone inhibits the
clearance of warfarin, and 1 of its metabolites, mon-
odesethylamiodarone, is a potent CYP2C9 inhibitor,
potentiating the anticoagulant effect (3).In this issue of the Journal, Flaker et al. (4) report
the outcomes associated with amiodarone among
patients participating in the ARISTOTLE (Apixaban
for Reduction in Stroke and Other Thromboembolic
Events in Atrial Fibrillation) trial, which com-
pared an oral Factor Xa inhibitor with warfarin for
stroke prevention. The exploratory post hoc analysis
provided insights into contemporary patterns of
amiodarone use and compared the incidence of
thromboembolism and bleeding in patients treated
concurrently with amiodarone and either warfarin or
apixaban.
As in most anticoagulation trials, patients with
paroxysmal AF represented only approximately one
third of the population enrolled in ARISTOTLE.
Amiodarone therapy was not randomized, but 11% of
patients were taking the drug at entry. There was
considerable geographic variation, with amiodarone
being used most frequently in Latin America (17.9%)
and Europe (12%) and used less frequently in Asian
Paciﬁc countries (9.5%) and North America (6.6%).
As catheter ablation procedures for rhythm control
become more widely adopted, one might speculate
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scribed less often.
Patients treated concurrently with warfarin had a
lower average time in the therapeutic range than
those not on amiodarone (56.6% vs. 63.0%; p <
0.0001). Although mortality and major bleeding rates
were not signiﬁcantly different between patients
managed with or without amiodarone, the combined
stroke or SEE rate was signiﬁcantly higher in patients
taking amiodarone. Analysis of interaction found no
signiﬁcant inﬂuence of amiodarone on the superior
efﬁcacy of apixaban seen in the trial as a whole
compared with warfarin. Patients taking amiodarone
experienced major bleeding more frequently with
concomitant warfarin than with apixaban.
Although the analysis did not permit exact under-
standing of the mechanisms leading to a higher
burden of stroke and SEEs in patients treated with
amiodarone, the lower time in the therapeutic range
in the subgroup on amiodarone and warfarin might
explain the trend. Because the reasons for therapy
were not known, those prescribed amiodarone could
have been at a higher intrinsic risk. It is tempting to
conclude that patients treated with amiodarone to
control AF might have better outcomes when anti-
coagulated with apixaban, and by extension, perhaps
one of the other target-speciﬁc oral anticoagulants
(e.g., the direct thrombin inhibitor dabigatran [RE-LY
(Randomized Evaluation of Long-Term Anticoagulant
Therapy) trial], or the Factor Xa inhibitors, rivaroxaban
[ROCKET-AF (Rivaroxaban Once Daily Oral Direct
Factor Xa Inhibition Compared With Vitamin K An-
tagonism for Prevention of Stroke and Embolism Trial
in Atrial Fibrillation)] or edoxaban [ENGAGE-AF– TIMI
48 (Effective Anticoagulation With Factor Xa Next
Generation in Atrial Fibrillation–Thrombolysis In
Myocardial Infarction 48) trial]), rather than warfarin.
Although initially developed as an antianginal
drug, clinicians have used amiodarone for >3 decades
to manage patients with AF, despite concerns about
potential side effects associated with long-term use.
In the CTAF (Canadian Trial of Atrial Fibrillation), 403
patients who had at least 1 episode of AF within
6 months were randomized to treatment with sotalol,
propafenone, or low-dose amiodarone. In CTAF, there
were no differences in mortality during a mean
follow-up of 16 months, but there was a trend toward
more frequent side effects with amiodarone, leading
to discontinuation of therapy (5). Amiodarone was
not associated with a higher risk of treatment-ending
side effects than sotalol in the AFFIRM trial (1). In
SAFE-T (Effective Anticoagulation With Factor Xa
Next Generation in Atrial Fibrillation–Thrombolysis
in Myocardial Infarction 48) (6), the only differencein adverse effects was a slight increase in minor
bleeding in patients treated with amiodarone. Mor-
tality was not signiﬁcantly greater with amiodarone
and sotalol than with placebo.
In the report by Flaker et al. (4), a trend toward
greater mortality in patients who received amiodarone
did not reach statistical signiﬁcance, which added to
the uncertainty raised by conﬂicting reports of mor-
tality (including noncardiovascular death) associated
with amiodarone. Considering that 2 prospective trials
of dronedarone (a less effective, but chemically-
related drug), in which mortality was part of the pri-
mary composite endpoint, yielded divergent results, it
is possible that the mortality signal arising from the
2,051 patients treated with amiodarone in ARISTOTLE
could dissipate if tested in a randomized format.
In this analysis from ARISTOTLE on the utiliza-
tion of amiodarone, a few limitations are worth
highlighting. Patients with permanent AF are not
generally considered candidates for antiarrhythmic
therapy, yet most patients who entered ARISTOTLE,
including those treated with amiodarone, were clas-
siﬁed as having persistent or permanent AF; the in-
vestigators did not distinguish these patterns from
one another. The duration of amiodarone treatment
was not speciﬁed and neither was information about
its efﬁcacy in maintaining sinus rhythm, which could
have implications for clinical outcomes and whether
these might differ in patients with recent-onset
versus long-standing AF. The analyses were not
adjusted for left ventricular ejection fraction or for
hepatic or renal disease, which could have contrib-
uted to the risks of thromboembolism and bleeding
that are difﬁcult to predict.
The challenges of amiodarone therapy are com-
pounded in patients with AF who receive warfarin
because of interactions that increase the risks of
complications of anticoagulation. The ARISTOTLE
investigators provided the ﬁrst report that assessed
the safety and efﬁcacy of this powerful antiar-
rhythmic drug in patients who received apixaban as
an alternative anticoagulant. Similar analyses of
outcomes among patients with AF in trials of other
target-speciﬁc anticoagulants could enhance our un-
derstanding of the safety and efﬁcacy of amiodarone
therapy in particular, and antiarrhythmic therapy in
general, without the encumbrances of warfarin.
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